About this Research Topic
In this Research Topic, we aim to identify and investigate novel applications of repositioned drugs for sensitizing P-gp overexpressing resistant cancer cells. Drug repositioning or drug repurposing is the application of known drugs for new indications. It has been used for the treatment of various diseases and has advantages, such as low cost and avoidance of a significant number of toxicity tests which is a time-consuming process. As these drugs are already used in clinical settings, drug repositioning would offer an efficient method to address the urgent need for pharmacological treatment of drug-resistant cancer, allowing the treatment of patients with drug-resistant disease at a relatively fast pace.
We welcome Original Research, Clinical Trial and Review articles including but not limited to the following topics:
1) Drug repositioning for P-glycoprotein overexpressing resistant cancer including products derived from original drugs as well as plant extracts or natural products which have been previously FDA-approved for human use.
2) Pharmacokinetics and pharmacodynamics of drugs with a relatively low half maximal inhibitory concentration (IC50) for a single treatment, when compared to non P-gp overexpressed sensitive (or parents) cancer cells.
3) Pharmacokinetics and pharmacodynamics of drugs with P-gp inhibitory activity for combination treatment with anti-cancer drugs.
4) Pharmacokinetics and pharmacodynamics of drugs with non P-gp inhibitory activity for combination treatment with anti-cancer drugs, in order to minimize any toxic effects due to P-gp inhibition.
Keywords: resistant cancer, P-glycoprotein, repositioning of drugs
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.